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The Escherichia coli AcrR multidrug-binding protein represses transcription of
acrAB and is induced by many structurally unrelated cytotoxic compounds. The
crystal structure of AcrR in space group P2221 has been reported previously.
This P2221 structure has provided direct information about the multidrug-
binding site and important residues for drug recognition. Here, a crystal
structure of this regulator in space group P31 is presented. Comparison of the
two AcrR structures reveals possible mechanisms of ligand binding and AcrR
regulation.
1. Introduction
The disturbing increase in multidrug resistance (MDR) observed in
bacteria is a growing problem associated with the use of antibiotics
for treating bacterial infections. Bacterial multidrug resistance is to a
large extent attributed to the expression of multidrug efflux trans-
porters that are capable of extruding a wide variety of toxic
compounds from bacterial cells (Levy, 1992, 2001; Saier et al., 1998;
McKeegan et al., 2003). Escherichia coli AcrB is one of the proto-
typical members of the resistance–nodulation–division (RND) family
of transporters (Tseng et al., 1999; Ma et al., 1995). This inner
membrane protein recognizes a variety of structurally dissimilar
agents, including most currently used antibiotics, chemotherapeutic
agents, detergents and dyes (Nikaido, 1996). In association with a
periplasmic membrane-fusion protein, AcrA (Zgurskaya & Nikaido,
2000), and an outer membrane channel, TolC (Koronakis et al., 2000),
the AcrB multidrug efflux pump is capable of exporting these
structurally dissimilar compounds directly to the external medium.
The transcription of acrAB is regulated by a global transcriptional
activator, MarA, and a local transcriptional repressor, AcrR (Ma et
al., 1996). AcrR is a 215-amino-acid protein that belongs to the TetR
family of transcriptional repressors (Ramos et al., 2005). Recently, the
ligand-free structure of AcrR has been determined in our laboratory
(Li et al., 2007). The crystal structure revealed that AcrR is a dimeric
two-domain molecule with an entirely helical architecture, similar to
other members of the TetR family. Each subunit of AcrR is composed
of nine helices (1–9 and 10–90, respectively). The smaller
N-terminal domain comprises helices 1–3, with 2 and 3 forming
the helix–turn–helix (HTH) DNA-binding motif. The larger
C-terminal domain consists of helices 4–9. The C-terminal domain
forms a large internal cavity that was suggested to serve as the
multidrug-binding pocket. Inside the drug-binding pocket, a com-
pletely buried negatively charged residue, Glu67, was found to be
critical for drug recognition (Li et al., 2007).
In E. coli, AcrR acts as a moderator to maintain sufficient ex-
pression levels of AcrB for bacterial survival in varying environments.
The induction of AcrR is triggered by many structurally unrelated
compounds, which are also substrates of the AcrB efflux pump. How
AcrR binds inducing ligands and regulates the expression of AcrB is
still not clear. The hypothesis is that binding of drugs to the
C-terminal ligand-binding domain of AcrR triggers a conformational
# 2008 International Union of Crystallography
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change in the N-terminal DNA-binding region, which results in the
release of AcrR from its operator DNA. Here, we report a new
crystal structure of AcrR with space group P31, which is distinct from
our previously reported P2221 space-group structure. A comparison
of these two structures reveals considerable conformational changes
in both the N-terminal and C-terminal regions, suggesting that these
two structures represent different conformational states of AcrR.
These crystal structures provide novel insight into the mechanisms of
ligand binding and AcrR regulation.
2. Materials and methods
2.1. Cloning, expression, purification, crystallization and data
collection
Recombinant AcrR containing a 6His tag at the C-terminus was
expressed in E. coli using the pET15b vector. The cloning, expression
and purification procedures have been described previously (Li et al.,
2006, 2007). For crystallization of native AcrR, a 4 ml drop consisting
of 2 ml protein solution (20 mM Tris pH 7.5, 60 mM imidazole and
200 mM NaCl) and 2 ml well solution (34% PEG 3350, 3% MPD,
0.2M MgCl2 and 0.1M Tris buffer pH 8.5) was equilibrated against
500 ml well solution. Under these conditions, a new bipyramidal
crystal shape was obtained. The crystals were subsequently found to
belong to space group P31. The SeMet-AcrR protein was crystallized
under conditions identical to those used for native AcrR. The crys-
tallization conditions provided sufficient cryoprotection and crystals
were frozen directly in liquid nitrogen at 100 K. Diffraction data sets
for both native and SeMet-AcrR were obtained at the Advanced
Photo Source (APS, beamline 24IDC) at cryogenic temperature
(100 K).
2.2. Structural determination and refinement
Diffraction data sets were processed with DENZO and scaled with
SCALEPACK (Otwinowski & Minor, 1997). In order to avoid any
model bias from using the P2221 structure of AcrR in molecular
replacement, we determined the new P31 structure of AcrR using
single-wavelength anomalous dispersion (SAD). The native and
SeMet crystals both belonged to space group P31; unit-cell para-
meters are summarized in Table 1. Following refinement of all 14
selenium sites of the AcrR dimer, initial phases were obtained by
SAD using the program BnP (Weeks et al., 2005). The electron-
density map was then subjected to density modification (DM) and the
initial model was obtained by the auto-interpretation routine func-
tion in the program RESOLVE (Terwilliger, 2001). After obtaining
the initial model, the program O (Jones et al., 1991) was used to
perform manual model building. The model was then refined against
the native data at 2.5 A˚ resolution using the programs CNS (Bru¨nger
et al., 1998) and REFMAC5 (Collaborative Computational Project,
Number 4, 1994; Murshudov et al., 1997). Solvent atoms were initially
built using the program ARP/wARP (Collaborative Computational
Project, Number 4, 1994; Lamzin & Wilson, 1993) and subsequently
added or removed by manual inspection. The final Rwork and Rfree
(calculated using 5% of reflections omitted from the refinement)
were 21.4% and 26.8%, respectively.
2.3. Protein Data Bank accession code
Coordinates and structural factors for the structure of AcrR have
been deposited in the RCSB Protein Data Bank with accession code
3bcg.
3. Results and discussion
3.1. N-terminal DNA-binding domain
The overall structure of AcrR in space group P31 is very similar to
the previously reported P2221 space-group structure (PDB code
2qop) at 2.5 A˚ resolution determined recently in our laboratory (Li et
al., 2007). Superimposition of these two dimeric structures gives an
overall r.m.s.d. of 1.4 A˚ calculated over the C atoms. However, a
detailed comparison reveals a significant conformational change in
the N-terminal DNA-binding domain. Fig. 1 illustrates a super-
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Table 1
Data-collection, phasing and structural refinement statistics.
Native SeMet, peak
Data collection
Wavelength (A˚) 0.9795 0.9795
Space group P31 P31
Unit-cell parameters (A˚) a = b = 46.7,
c = 166.2
a = b = 46.6,
c = 166.7
Resolution (A˚) 2.5 (2.57–2.48) 2.7 (2.84–2.74)
Completeness (%) 97.7 (84.5) 97.1 (91.1)
Total No. of reflections 466209 398102
No. of unique reflections 14362 11236
Rmerge (%) 5.1 (24.4) 5.7 (11.8)
hI/(I)i 23.2 (4.0) 45.4 (8.3)
Phasing
Se-atom sites 14
Resolution range of data used (A˚) 50–2.80
Overall figure of merit 0.39
Refinement
Rwork (%) 21.4
Rfree (%) 26.8
Wilson B (A˚2) 62.6
hBi (A˚2) 69.9
R.m.s. deviations†
Bond angles () 1.1
Bond lengths (A˚) 0.007
Ramachandran analysis‡
Most favored (%) 83.4
Allowed (%) 14.7
Generously allowed (%) 1.8
Disallowed (%) 0.0
† Engh & Huber (1991). ‡ Calculated using PROCHECK (Laskowski et al., 1993).
Figure 1
Structural comparison of the P31 and P2221 structures of AcrR. Superimposition of
the dimeric AcrR structures was performed using the program ESCET (orange, P31
structure; green, P2221 structure).
position of these two AcrR structures using the program ESCET
(Schneider, 2002). A plot of the distance between corresponding C
atoms in the two dimeric AcrR structures with respect to residue
number is shown in Fig. 2(a). The plot indeed suggests that the main
difference in conformation between these two structures originates
from helix 1 through the N-terminal half of helix 4. This change
results in an overall r.m.s.d. of 2.8 A˚ for the C atoms in the
N-terminal domains (residues 7–65), in contrast to the <0.7 A˚ r.m.s.d.
of the C-terminal domains (residues 73–210). Fig. 2(b) illustrates an
error-scaled distance difference matrix (ESCET plot; Schneider,
2002) calculated between the P31 and P2221 structures.
Judging from the two crystal structures of AcrR, the conforma-
tional changes between the P31 and P2221 structures seem to be
predominantly rigid-body translation and rotation of the N-terminal
domain. These movements lead to a downward shift of the entire
N-terminal DNA-binding domain of the P31 structure (with respect
to the orientation shown in Fig. 1) by 2.6 A˚ and a rotation of 10
towards the subunit interface of the dimer when compared with that
of the P2221 structure (Fig. 1). As a consequence of these movements,
the two N-terminal domains of the AcrR dimer in the P31 structure
protein structure communications
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Figure 2
Structural rearrangement of the N-terminal domain of AcrR. (a) Plot of the
distance between corresponding C atoms in AcrR after superposition of the
dimeric P31 and P2221 structures. (b) Error-scaled distance difference matrix
(ESCET plot) calculated between the dimeric P31 and P2221 AcrR structures.
Figure 3
Electron-density maps of the P31 structure. (a) The 2Fobs – Fcalc electron-density
map (blue), contoured at 1.0, of the recognition helix 3 (orange, P31 structure;
green, P2221 structure). (b) The 2Fobs  Fcalc electron-density map (blue),
contoured at 1.0, of the flexible loop between helices 4a and 4b (orange, P31
structure; green, P2221 structure).
come closer to each other by approximately 2 A˚. The center-to-center
distance between recognition helices 3 and 30 (as measured by the
distance between the C atoms of Tyr49 and Tyr490) decreases from
42 A˚ in the P2221 structure to 39 A˚ in the P31 structure. To bind two
consecutive major grooves of B-DNA, the center-to-center distance
has to be 34 A˚. This distance is thought to increase upon drug
binding, which in turn inhibits the binding of the regulator to its
operator DNA. Thus, this center-to-center distance can reflect
different conformational states of the regulator. For CmeR, the
corresponding center-to-center distance was measured to be 54 A˚.
The relatively large center-to-center distance observed in CmeR
suggested that CmeR was in a ligand-bound state (Gu et al., 2007). In
the case of QacR, the center-to-center distance is 39 A˚ for apo-QacR
(Schumacher et al., 2001). Upon DNA and drug binding to QacR, the
corresponding center-to-center distances become 37 and 48 A˚,
respectively (Schumacher et al., 2002). Because of these center-to-
center distances, it is likely that the structure of the DNA-bound form
of AcrR is more similar to the P31 structure, while its drug-bound
form is more closely related to the P2221 conformation.
In addition to these differences, Arg45, an N-terminal amino acid
which has been identified to be indispensable for DNA binding and
important for AcrR regulation (Webber & Piddock, 2001), undergoes
a significant conformational change. The C—C distance between
Arg45 and Arg450 decreases from 40 A˚ in the P2221 structure to 35 A˚
in the P31 structure. A comparison of the conformation of helix 3 in
the two AcrR structures is shown in Fig. 3(a).
We analyzed the normal modes of vibration of the P31 structure of
AcrR using the program ElNe´mo (Suhre & Sanejouand, 2004a,b).
The results suggest that the lowest frequency nontrivial vibrational
mode indeed corresponds to the swinging motion of the entire
N-terminal DNA-binding domain. This swinging motion highlights
the transition between the P31 and P2221 structures. Accompanied by
this N-terminal swinging motion, the COOH-terminus of helix 4a
and the NH2-terminus of helix 6 perform helix-to-coil transitions in
this vibrational mode. These shifts in conformation of helices 4 and
6 are also consistent with the observed difference between the two
AcrR structures, as discussed below.
3.2. C-terminal regulatory domain
One unique feature found in the crystal structure of AcrR is the
presence of a short loop in the middle of helix 4. To better facilitate
comparison with the structures of other TetR members, residues 55–
65 and 69–80 in the P2221 structure were assigned as helices 4a and
4b, respectively (Li et al., 2007). The short loop between 4a and
4b acts as a transition region connecting the N-terminal and
C-terminal domains. In the P2221 structure, this flexible loop consists
of residues 66–68. In the P31 structure, however, this loop contains
four more residues (66–72). Unlike the conformational change in the
N-terminal domain, which is mainly an overall shift in position of the
entire domain, the changes in the C-terminal domain of these two
conformations are predominately associated with local movements of
the flexible loop between 4a and 4b and helices 4 and 6.
It has been found that Glu67, a completely buried residue in the
drug-binding pocket of the P2221 structure, is critical for drug
recognition (Li et al., 2007). In the P31 structure, Glu67 is expelled
from the hydrophobic core into the solvent (Figs. 1 and 3b). The shift
in the C atom of this residue reaches 4.2 A˚when compared with that
of the P2221 structure. In addition, the side chain of Glu67 flips away
from the hydrophobic core of the drug-binding pocket. This results in
a positional shift of the two carboxylate O atoms (OE1 and OE2) in
the side chain of Glu67 by more than 10 A˚when compared with those
of the P2221 structure. The nearby flexible-loop residues between 4a
and 4b also shift considerably in response to this large movement
(Fig. 3b). Coupled with the movement of Glu67, helix 4a shifts
toward the N-terminal DNA-binding domain by 2.3 A˚ in the P31
structure when compared with the P2221 structure (Fig. 1).
Comparison of the P2221 and P31 structures also reveals confor-
mational changes in helix 6. Arg105 and Arg106 in the P31 structure
shift in position, leading to an unwinding of the helical residues
Glu104–Arg106 at the N-terminus of 6. Thus, helix 6 is shortened
by one turn in the P31 structure. This change may be attributed to the
movement of the flexible loop between 4a and 4b. In the P2221
structure, Arg106 is hydrogen bonded to Glu67 (Fig. 4). This
hydrogen bond is missing in the P31 structure owing to the expulsion
of Glu67 from the hydrophobic core. As a consequence, this motion
induces a helix-to-coil transition of helix 6. In addition to the above
change, it was found that Arg105 is hydrogen bonded to residues
Gln14 and Asp18 in the P2221 structure (Fig. 4). These hydrogen
bonds are also missing in the P31 structure.
Based on the P31 and P2221 structures of AcrR, we suspect that the
changes in the conformation of the N-terminal DNA-binding and
C-terminal drug-binding domains of AcrR are cooperative owing to
the formation of hydrogen bonds at the interface between these two
domains (Fig. 4). In the DNA-bound form of AcrR, the structure of
the regulator may be closer to the P31 structure. Thus, the side chain
of Glu67 may point outside the drug-binding pocket and be exposed
to the solvent. Drug binding to the C-terminal domain may induce
conformational changes that result in a conformation more closely
related to the P2221 structure, in which the side chain of Glu67 flips
into the interior of the hydrophobic core. This change may also be
accompanied by the formation of new hydrogen bonds between
Glu67 and Arg106, Arg105 and Gln14, and Arg105 and Asp18. The
protein structure communications
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Figure 4
Hydrogen bonds at the interface between the C-terminal and N-terminal domains
of one subunit of the P2221 structure of AcrR. The hydrogen bonds, shown as
dotted lines, are between Glu67 and Arg106, between Gln14 and Arg105 and
between Asp18 and Arg105. These hydrogen bonds are absent in the P31 structure.
The orientation of this figure is the same as that of Fig. 1.
crystal structures of both DNA-bound and drug-bound AcrR would
be necessary to confirm the change in conformation upon DNA and
drug binding.
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